OST-577 human anti-hepatitis B monoclonal antibody data

PDLI reported that it saw reductions in key measures of hepatitis B after only a month of treatment in a Phase I/II open label trial in 12 patients with chronic active hepatitis B.

As reported at the Seventh International Conference on Antiviral Research, five patients received doses of 0.5 mg/kg, five got 1 mg/kg, and three were at 2 mg/kg. Patients received seven intravenous infusions in the first 35 days of the study and were followed for up to 158 days. One patient at the highest dose dropped out. ...